Speakers

Dr. Madan Mohan Gupta

Dr. Madan Mohan Gupta

Senior Lecturer, School of Pharmacy, UWI

Standardization, Measurement & Quality Assurance Drugs

Presently working as Senior Lecturer in Pharmaceutics at School of Pharmacy, Faculty of Medical Sciences, The University of The West Indies, St. Augustine, Trinidad& Tobago, WI. He is also Chairman of Research Committee of School of Pharmacy, Faculty of Medical Sciences, The University of The West Indies, St. Augustine, Trinidad& Tobago. He Developed a Laboratory of Pharmaceutical Formulation Development and Design in the School of Pharmacy, Faculty of Medical Sciences, The University of The West Indies, St. Augustine, Trinidad& Tobago.

Dr. Sameer Dhingra

Dr. Sameer Dhingra

PhD, Lecturer, School of Pharmacy, Faculty of Medical Sciences,The University of the West Indies, St. Augustine

Pharmacovigilance : A Local Perspective

TOPIC SUMMARY: Adverse drug reactions (ADRs) are one of the leading causes of morbidity and mortality. In its simplest definition, an ADR is any undesirable effect of a drug beyond its anticipated therapeutics occurring during clinical use. The World Health Organization (WHO) defines an ADR as “a response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function”.

Dr. Rian Marie Extavour

Dr. Rian Marie Extavour

B.Sc. Pharm, M.Sc. (Clinical Pharmacy, Aberdeen UK), PgCert (Univ Teaching & Learning, UWI), M.Sc. (Pharmacovigilance & Pharmacoepidemiology, Bordeaux France), Ph.D.(Clinical and Administrative Pharmacy, Athens, GA USA), RPh

Challenges to Patient Safety : Internet Pharmacies

The introduction of internet or online pharmacies has created opportunities for businesses as well as convenience for patients and caregivers by providing access to a wider selection of medicines than traditional brick-and-mortar pharmacies. However, in the absence of strict regulation, online pharmacies may become channels for substandard, falsified, unregistered or counterfeit medicinal products to enter local markets.

Dr. Rajiv Dahiya

Dr. Rajiv Dahiya

Director, School of Pharmacy, UWI, St. Augustine

Emerging Technologies for Identifying Counterfeit Drugs

Summary: The globalization of the pharmaceutical supply chain has introduced new challenges especially related to substandard and falsified medicines. As the manufacture, supply, and distribution of drugs becomes more complex, the need for innovative technologies to detect counterfeit drugs is constantly increasing. With counterfeit medicines occupying at least 10-30% of the market in resource-limited areas, millions of people receive inadequate treatment for illnesses.

Mr. Francis Burnett

Mr. Francis Burnett

Head of the Organisation of Eastern Caribbean States/ Pharmaceutical Procurement Service (OECS/PPS)

The Caribbean Story :The Role of Governmental Agencies in Drug Counterfeiting

Francis Burnett is the Head of the Organisation of Eastern Caribbean States/ Pharmaceutical Procurement Service (OECS/PPS), which is responsible for supply chain management of medicines and related medical products for its nine member countries. He holds a Bachelor of Science degree in Pharmacy from Canada, and diplomas in health education and business administration from the University of the West Indies.

Dr. Devendra Singh

Dr. Devendra Singh

Obstetrics & Gynecology Department, Eastern Regional Health Authority, Trinidad

The Role of Patients, Doctors, Pharmacists and Caregivers

I am a Specialist Obstetrician & Gynaecologist with over 20 years’ experience in the field. I have spent over 12 years in the United Kingdom where most of my training has taken place. I was a Consultant Ob/Gyn in Manchester which was the second largest maternity unit in the UK. I returned to Trinidad as a Lecturer with the University of the West Indies and served for the past 3 years. I am currently the Ag.Head of Department in Obstetrics & Gynaecology at the Sangre Grande Hospital.

Mrs. Christine de Coteau Lavine

Mrs. Christine de Coteau Lavine

District Manager - Trinidad, Pfizer

Chairperson

Mrs. Christine de Coteau Lavine has been working in the Pharmaceutical Industry for the past thirty (30) years.
She has worked with one of the top Pharmaceutical Companies throughout her entire career having worked the ranks and excelled in the positions as Medical Representative, Senior Medical Representative and currently that of District manager.

Mr. Percival A. Jordan

Mr. Percival A. Jordan

Pfizer Security Consultant

A Manufacturer / Distributor Perspective on Counterfeiting

Mr. Percival A. Jordan, retired as Supervisory Special Agent, in 2003 from the United Customs Service/U.S. Department of Homeland Security with over 30 years in U.S Federal Law Enforcement service, where he served as Assistant Attache, and Customs Attache at the U.S. Embassy in Venezuela, with responsibilities for Ecuador, Peru, Ecuador, Suriname, Guyana, French Guyana, etc. In conjunction with these countries, he has worked continuously in Central America, and the Caribbean.

Prof. Francisco Donadío, RPh, MHSM. MSc

Prof. Francisco Donadío, RPh, MHSM. MSc

Product Patrimony Management Head for Pacific, Central America and the Caribbean, Sanofi

Pharmaceutical Counterfeiting – A Global Treat

Topic Summary: Counterfeit drugs are harmful for human health. The fact that these products are made to make profit out of human lives, makes this business a crime. We need to know what are they, how they might be manufactured, how harmful they can be, how much profit they can make but also how we can fight against them, towards awareness, education and some tips on how they can be recognized.

Dr. Vishwanath Andy Partapsingh

Dr. Vishwanath Andy Partapsingh

MBBS, M.Sc, DM, MPH, Chief Medical Officer

Open Remarks

Vishwanath Andy Partapsingh is a public health physician dedicated to strengthening health systems in the Caribbean sub-region with a focus on policy translation into action. He has spent the past 6 years working at the policy development and political leadership level in Trinidad and Tobago. This policy development experience is supported by 10 years of clinical experience including hospital-based intensive care and community-based primary care.